ArticleAnnals of translational medicine2018

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.

Constantine E Kosmas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.